Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3923]

FORTE trial: Minimal residual disease evaluation in newly diagnosed multiple...

Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy

FORTE trial: Minimal residual disease evaluation in newly diagnosed multiple myeloma ( Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy )

The PANDA study: Combining panitumumab with FOLFOX or 5FU in elderly patients...

Dr Sara Lonardi - Istituto Oncologico Veneto, Padua, Italy

The PANDA study: Combining panitumumab with FOLFOX or 5FU in elderly patients with RAS-BRAF WT metastatic colorectal cancer ( Dr Sara Lonardi - Istituto Oncologico Veneto, Padua, Italy )

Comparing pevonedistat plus azacitidine versus azacitidine alone in patients...

Prof Lionel Ades - Hôpital Saint-Louis, Paris, France

Comparing pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk MDS/CMML or low-blast AML ( Prof Lionel Ades - Hôpital Saint-Louis, Paris, France )

ASCO 2020 prostate cancer highlights

Prof Karim Fizazi, Prof Axel Merseburger, Dr Kim Chi and Prof Amit Bahl

ASCO 2020 prostate cancer highlights ( Prof Karim Fizazi, Prof Axel Merseburger, Dr Kim Chi and Prof Amit Bahl )

COVID-19: Optimising supportive care during active cancer treatment

Dr Paul Cornes - Comparative Outcomes Group, Bristol, UK

COVID-19: Optimising supportive care during active cancer treatment ( Dr Paul Cornes - Comparative Outcomes Group, Bristol, UK )

ASCO 2020: Updates in renal cancer

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

ASCO 2020: Updates in renal cancer ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

TROPHIMMUN: Avelumab for gestational trophoblastic tumours resistant to...

Prof Benoit You - Hospices Civils de Lyon, Lyon, France

TROPHIMMUN: Avelumab for gestational trophoblastic tumours resistant to monochemotherapy ( Prof Benoit You - Hospices Civils de Lyon, Lyon, France )

KEYNOTE-177 results: Pembrolizumab versus chemotherapy for patients with MSI-H...

Prof Thierry Andre - Sorbonne University and Saint-Antoine Hospital, Paris...

KEYNOTE-177 results: Pembrolizumab versus chemotherapy for patients with MSI-H/dMMR colorectal cancer ( Prof Thierry Andre - Sorbonne University and Saint-Antoine Hospital, Paris, France )

PARP inhibitors in prostate cancer: Guidelines, who to test and the patient...

Dr Neal Shore and Dr Elena Castro

PARP inhibitors in prostate cancer: Guidelines, who to test and the patient pathway ( Dr Neal Shore and Dr Elena Castro )

New emerging treatment options and targeted therapies for bladder cancer

Dr Arlene Siefker-Radtke and Dr Yohann Loriot

New emerging treatment options and targeted therapies for bladder cancer ( Dr Arlene Siefker-Radtke and Dr Yohann Loriot )

Conducting Oncology Clinical Trials in Africa II: ACTC Informational Session

Prof Folakemi Odedina, Prof Ifeoma Okoye and Prof Delva Shamley

Conducting Oncology Clinical Trials in Africa II: ACTC Informational Session ( Prof Folakemi Odedina, Prof Ifeoma Okoye and Prof Delva Shamley )

Timing of response to venetoclax combination treatment in older patients with...

Dr Brian Jonas - University of California Davis Comprehensive Cancer Center...

Timing of response to venetoclax combination treatment in older patients with acute myeloid leukaemia ( Dr Brian Jonas - University of California Davis Comprehensive Cancer Center, Sacramento, USA )

More from ecancer